Evotec consents to transfer property in France - Evotec consents to transfer property in France
Evotec, a prominent biotech conglomerate based in Hamburg, has announced a significant deal with Swiss pharmaceutical company Sandoz. In this agreement, Evotec will sell its biologics manufacturing site in Toulouse, France, for approximately $300 million in cash, with additional technology-related considerations, future development revenues, milestones, and product royalties [2][3].
Located in France, the Toulouse site is one of Evotec's sites situated outside the United States. It has been fully occupied by Sandoz since July 2024, and the deal will transfer full ownership of the biosimilar manufacturing capabilities to Sandoz [2][3]. This move is part of Evotec's ongoing restructuring efforts, aiming to create a more asset-light business model and maintain a focus on high-margin offerings [2][3][5].
The sale will provide Evotec with immediate cash proceeds, and the company expects to see improvements in its revenue mix, profit margins, and capital efficiency due to reduced fixed asset burden [2][3]. Despite selling the physical site, Evotec will retain revenue upside through licensing and milestone agreements tied to the technology [2][3][5].
The agreement between Evotec and Sandoz includes the transfer of a license for the production of certain generic drugs. This aspect of the deal underscores the comprehensive nature of the transaction, ensuring Sandoz can fully leverage Evotec's advanced continuous manufacturing technology [2][3].
However, it's important to note that the deal is still non-binding, pending employee consultation processes, contractual agreements, and regulatory approvals. Closing is expected in the fourth quarter of 2025 [2][3].
Evotec operates multiple sites in both Europe and the United States, with the sale of the Toulouse site representing a strategic shift in its European operations. The company continues to maintain a strong presence in the United States, with sites located there as well.
In summary:
| Aspect | Detail | |----------------------------|---------------------------------------------------------------------------------------------| | Asset being sold | Just – Evotec Biologics site in Toulouse, focused on biologics manufacturing | | Buyer | Sandoz AG | | Sale price | Approximately USD 300 million in cash, plus technology-related considerations and royalties | | Strategic reasons | Move to asset-light model, improve revenue mix, margin, and capital efficiency | | Economic implications | Upfront cash, plus ongoing income from licenses, milestones, and royalties | | Status | Non-binding agreement signed; pending employee consultation, contracts, regulatory approval | | Expected closing | Q4 2025 |
This sale marks a significant step in Evotec’s restructuring to enhance financial performance while maintaining strategic collaboration with Sandoz on biologics development [3][2].
In the context of Evotec's restructuring, the company is reinforcing its collaboration with Sandoz by selling its biologics manufacturing site in Toulouse, France, through a non-binding agreement worth approximately $300 million in cash. This move, aimed at enhancing financial performance, coincides with the exploration of vocational training opportunities, such as in science, industry, and finance, which could further support the company's asset-light business model and high-margin offerings.
